Precision medicine in breast cancer: reality or utopia?

被引:51
作者
Bettaieb, Ali [1 ,2 ,8 ]
Paul, Catherine [1 ,2 ]
Plenchette, Stephanie [1 ,2 ]
Shan, Jingxuan [3 ]
Chouchane, Lotfi [3 ]
Ghiringhelli, Francois [4 ,5 ,6 ,7 ]
机构
[1] PSL Res Univ, Lab Immunol & Immunotherapie Canc, EPHE, F-75000 Paris, France
[2] Univ Bourgogne Franche Comte, LIIC, EA7269, F-21000 Dijon, France
[3] Qatar Fdn, Lab Genet Med & Immunol, Weill Cornell Med Qatar, Doha, Qatar
[4] Ctr Georges Francois Leclerc, Dept Oncol Med, F-21000 Dijon, France
[5] Ctr Georges Francois Leclerc, Plateforme Transfert & Biol Cancerol, F-21000 Dijon, France
[6] Univ Bourgogne Franche Comte, UMR 1231, INSERM, UFR Sci Sante, F-21000 Dijon, France
[7] Univ Bourgogne, F-21000 Dijon, France
[8] Univ Bourgogne, Immunol & Immunotherapy Canc Lab, EA7269, EPHE, 7 Bd Jeanne Arc, F-21079 Dijon, France
关键词
Breast cancer; Molecular subtypes; Triple-negative; HER2+; Tumor heterogeneity; Precision medicine; Chemotherapy; Immunotherapy; Phase III clinical trials; TUMOR-INFILTRATING LYMPHOCYTES; PATHOLOGICAL COMPLETE RESPONSE; CELL-FREE DNA; ESTROGEN-RECEPTOR; ESR1; MUTATIONS; NEOADJUVANT CHEMOTHERAPY; PROGESTERONE-RECEPTOR; PROGNOSTIC VALUE; FREE SURVIVAL; OPEN-LABEL;
D O I
10.1186/s12967-017-1239-z
中图分类号
R-3 [医学研究方法]; R3 [基础医学];
学科分类号
1001 ;
摘要
Many cancers, including breast cancer, have demonstrated prognosis and support advantages thanks to the discovery of targeted therapies. The advent of these new approaches marked the rise of precision medicine, which leads to improve the diagnosis, prognosis and treatment of cancer. Precision medicine takes into account the molecular and biological specificities of the patient and their tumors that will influence the treatment determined by physicians. This new era of medicine is accessible through molecular genetics platforms, the development of high-speed sequencers and means of analysis of these data. Despite the spectacular results in the treatment of cancers including breast cancer, described in this review, not all patients however can benefit from this new strategy. This seems to be related to the many genetic mutations, which may be different from one patient to another or within the same patient. It comes to give new impetus to the research-both from a technological and biological point of view-to make the hope of precision medicine accessible to all.
引用
收藏
页数:13
相关论文
共 121 条
[1]  
Abe O, 2005, LANCET, V366, P2087, DOI 10.1016/s0140-6736(05)66544-0
[2]   Prognostic Value of Tumor-Infiltrating Lymphocytes in Triple-Negative Breast Cancers From Two Phase III Randomized Adjuvant Breast Cancer Trials: ECOG 2197 and ECOG 1199 [J].
Adams, Sylvia ;
Gray, Robert J. ;
Demaria, Sandra ;
Goldstein, Lori ;
Perez, Edith A. ;
Shulman, Lawrence N. ;
Martino, Silvana ;
Wang, Molin ;
Jones, Vicky E. ;
Saphner, Thomas J. ;
Wolff, Antonio C. ;
Wood, William C. ;
Davidson, Nancy E. ;
Sledge, George W. ;
Sparano, Joseph A. ;
Badve, Sunil S. .
JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (27) :2959-+
[3]  
Allison KH, 2014, ONCOLOGY-NY, V28, P772
[4]   Prospective Study Evaluating the Impact of Tissue Confirmation of Metastatic Disease in Patients With Breast Cancer [J].
Amir, Eitan ;
Miller, Naomi ;
Geddie, William ;
Freedman, Orit ;
Kassam, Farrah ;
Simmons, Christine ;
Oldfield, Maria ;
Dranitsaris, George ;
Tomlinson, George ;
Laupacis, Andreas ;
Tannock, Ian F. ;
Clemons, Mark .
JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (06) :587-592
[5]  
[Anonymous], 2018, N Engl J Med, V379, P2582, DOI 10.1056/NEJMx180043
[6]   The evolving concept of cancer and metastasis stem cells [J].
Baccelli, Irene ;
Trumpp, Andreas .
JOURNAL OF CELL BIOLOGY, 2012, 198 (03) :281-293
[7]   Targeting Cellular Signaling Pathways in Breast Cancer Stem Cells and its Implication for Cancer Treatment [J].
Barreto Pires, Bruno Ricardo ;
Soares De Amorim, Isis Salviano ;
Duarte E Souza, Layane ;
Rodrigues, Juliana Alves ;
Mencalha, Andre Luiz .
ANTICANCER RESEARCH, 2016, 36 (11) :5681-5691
[8]   Pertuzumab plus Trastuzumab plus Docetaxel for Metastatic Breast Cancer [J].
Baselga, Jose ;
Cortes, Javier ;
Kim, Sung-Bae ;
Im, Seock-Ah ;
Hegg, Roberto ;
Im, Young-Hyuck ;
Roman, Laslo ;
Pedrini, Jose Luiz ;
Pienkowski, Tadeusz ;
Knott, Adam ;
Clark, Emma ;
Benyunes, Mark C. ;
Ross, Graham ;
Swain, Sandra M. .
NEW ENGLAND JOURNAL OF MEDICINE, 2012, 366 (02) :109-119
[9]   Descriptive analysis of estrogen receptor (ER)negative, progesterone receptor (PR)-negative, and HER2-negative invasive breast cancer, the so-called triple-negative phenotype - A population-based study from the California Cancer Registry [J].
Bauer, Katrina R. ;
Brown, Monica ;
Cress, Rosemary D. ;
Parise, Carol A. ;
Caggiano, Vincent .
CANCER, 2007, 109 (09) :1721-1728
[10]   Familial breast cancer: collaborative reanalysis of individual data from 52 epidemiological studies including 58 209 women with breast cancer and 101 986 women without the disease [J].
Beral, V ;
Bull, D ;
Doll, R ;
Peto, R ;
Reeves, G .
LANCET, 2001, 358 (9291) :1389-1399